GoHealth Reports Strong Fourth Quarter and Fiscal Year 2024 Results, Driven by a Successful Annual Enrollment Period
GoHealth (NASDAQ: GOCO) reported strong Q4 2024 results with net revenues of $389.1 million, up 41% year-over-year. The company achieved significant growth with 481,445 submissions, a 67% increase from the previous year.
Q4 highlights include net income of $58.0 million, improving by $60.3 million, and Adjusted EBITDA of $117.8 million, up 107%. Direct Operating Cost per Submission improved 27% to $501.
Full-year 2024 performance showed net revenues of $798.9 million (9% growth), with 1,016,182 submissions (23% increase). The company reduced its net loss to $7.3 million, a $144.0 million improvement. Key achievements include successful refinancing of credit facility, implementation of PlanFit Save initiative, and supporting nearly 3 million Medicare consumers.
GoHealth (NASDAQ: GOCO) ha riportato risultati solidi per il quarto trimestre del 2024 con entrate nette di 389,1 milioni di dollari, in aumento del 41% rispetto all'anno precedente. L'azienda ha ottenuto una crescita significativa con 481.445 invii, un incremento del 67% rispetto all'anno scorso.
I punti salienti del quarto trimestre includono un reddito netto di 58,0 milioni di dollari, migliorato di 60,3 milioni di dollari, e un EBITDA rettificato di 117,8 milioni di dollari, in aumento del 107%. Il costo operativo diretto per invio è migliorato del 27% a 501 dollari.
La performance dell'intero anno 2024 ha mostrato entrate nette di 798,9 milioni di dollari (crescita del 9%), con 1.016.182 invii (aumento del 23%). L'azienda ha ridotto la sua perdita netta a 7,3 milioni di dollari, un miglioramento di 144,0 milioni di dollari. Tra i risultati chiave ci sono il rifinanziamento riuscito della linea di credito, l'implementazione dell'iniziativa PlanFit Save e il supporto a quasi 3 milioni di consumatori Medicare.
GoHealth (NASDAQ: GOCO) reportó resultados sólidos para el cuarto trimestre de 2024 con ingresos netos de 389,1 millones de dólares, un aumento del 41% en comparación con el año anterior. La compañía logró un crecimiento significativo con 481,445 solicitudes, un incremento del 67% respecto al año pasado.
Los aspectos destacados del cuarto trimestre incluyen un ingreso neto de 58,0 millones de dólares, mejorando en 60,3 millones de dólares, y un EBITDA ajustado de 117,8 millones de dólares, un aumento del 107%. El costo operativo directo por solicitud mejoró un 27% a 501 dólares.
El rendimiento del año completo 2024 mostró ingresos netos de 798,9 millones de dólares (crecimiento del 9%), con 1,016,182 solicitudes (aumento del 23%). La compañía redujo su pérdida neta a 7,3 millones de dólares, una mejora de 144,0 millones de dólares. Los logros clave incluyen el exitoso refinanciamiento de la línea de crédito, la implementación de la iniciativa PlanFit Save y el apoyo a casi 3 millones de consumidores de Medicare.
GoHealth (NASDAQ: GOCO)는 2024년 4분기 강력한 실적을 발표했습니다. 순수익 3억 8,910만 달러로 전년 대비 41% 증가했습니다. 회사는 481,445건의 제출로 67%의 성장을 달성했습니다.
4분기 주요 내용으로는 순이익 5,800만 달러로 6,030만 달러 개선되었고, 조정 EBITDA 1억 1,780만 달러로 107% 증가했습니다. 제출당 직접 운영 비용은 27% 개선되어 501달러가 되었습니다.
2024년 전체 성과는 순수익 7억 9,890만 달러 (9% 성장)로, 1,016,182건의 제출 (23% 증가)을 기록했습니다. 회사는 순손실을 730만 달러로 줄였으며, 이는 1억 4,400만 달러의 개선입니다. 주요 성과로는 신용 시설의 성공적인 재융자, PlanFit Save 이니셔티브의 실행, 거의 300만 명의 메디케어 소비자 지원이 포함됩니다.
GoHealth (NASDAQ: GOCO) a annoncé de solides résultats pour le quatrième trimestre 2024 avec des revenus nets de 389,1 millions de dollars, en hausse de 41 % par rapport à l'année précédente. L'entreprise a connu une croissance significative avec 481 445 soumissions, soit une augmentation de 67 % par rapport à l'année précédente.
Les points forts du quatrième trimestre incluent un revenu net de 58,0 millions de dollars, amélioré de 60,3 millions de dollars, et un EBITDA ajusté de 117,8 millions de dollars, en hausse de 107 %. Le coût d'exploitation direct par soumission s'est amélioré de 27 % pour atteindre 501 dollars.
Les performances de l'année 2024 ont montré des revenus nets de 798,9 millions de dollars (croissance de 9 %), avec 1 016 182 soumissions (augmentation de 23 %). L'entreprise a réduit sa perte nette à 7,3 millions de dollars, soit une amélioration de 144,0 millions de dollars. Parmi les réalisations clés figurent le refinancement réussi de la ligne de crédit, la mise en œuvre de l'initiative PlanFit Save et le soutien à près de 3 millions de consommateurs de Medicare.
GoHealth (NASDAQ: GOCO) hat starke Ergebnisse für das vierte Quartal 2024 gemeldet, mit Netto-Einnahmen von 389,1 Millionen Dollar, was einem Anstieg von 41 % im Vergleich zum Vorjahr entspricht. Das Unternehmen erzielte ein signifikantes Wachstum mit 481.445 Einreichungen, was einem Anstieg von 67 % im Vergleich zum Vorjahr entspricht.
Die Höhepunkte des vierten Quartals umfassen einen Nettogewinn von 58,0 Millionen Dollar, was eine Verbesserung um 60,3 Millionen Dollar darstellt, und ein bereinigtes EBITDA von 117,8 Millionen Dollar, was einem Anstieg von 107 % entspricht. Die direkten Betriebskosten pro Einreichung verbesserten sich um 27 % auf 501 Dollar.
Die Gesamtjahresleistung 2024 zeigte Netto-Einnahmen von 798,9 Millionen Dollar (9 % Wachstum), mit 1.016.182 Einreichungen (23 % Anstieg). Das Unternehmen reduzierte seinen Nettoverlust auf 7,3 Millionen Dollar, eine Verbesserung um 144,0 Millionen Dollar. Zu den wichtigsten Erfolgen gehören die erfolgreiche Refinanzierung der Kreditfazilität, die Implementierung der PlanFit Save-Initiative und die Unterstützung von fast 3 Millionen Medicare-Kunden.
- Q4 net revenues up 41% to $389.1M
- Q4 submissions increased 67% to 481,445
- Q4 net income of $58.0M, up $60.3M YoY
- Q4 Adjusted EBITDA up 107% to $117.8M
- Operating Cost per Submission improved 27%
- Full-year submissions up 23% to 1,016,182
- Net loss improved by $144.0M YoY
- Successfully refinanced credit facility
- Full-year net loss of $7.3M
Insights
GoHealth's Q4 and FY 2024 results reveal a company hitting an inflection point in its Medicare marketplace business. The Q4 performance shows remarkable momentum with
The
The successful integration of e-TeleQuote appears to be a key driver of these improvements, suggesting the acquisition is delivering synergies beyond initial expectations. Their technology investments in AI and analytics are clearly bearing fruit in operational efficiency, helping them serve nearly 3 million Medicare consumers in 2024.
The refinancing of their credit facility with a new five-year term provides important financial flexibility as they continue scaling operations. This improved capital structure, combined with their new PlanFit Save initiative generating compensation for membership retention, positions GoHealth to potentially achieve sustained profitability in 2025.
While management expresses optimism about favorable market conditions continuing through Q3 2025, investors should note the highly seasonal nature of this business. The Annual Enrollment Period in Q4 drives disproportionate revenue and profit, making year-over-year Q4 comparisons particularly important for assessing long-term trajectory.
CHICAGO, Feb. 27, 2025 (GLOBE NEWSWIRE) -- GoHealth, Inc. (NASDAQ: GOCO) (“GoHealth” or the “Company”), a leading health insurance marketplace and Medicare-focused digital health company, today announced financial results for the three and twelve months ended December 31, 2024.
Fourth Quarter Highlights
- Achieved net revenues of
$389.1 million , a substantial41% increase compared to the prior year period.
- Submissions grew to 481,445, representing a
67% increase compared to the prior year period.
- Net income of
$58.0 million , a substantial improvement of$60.3 million compared to the prior year period.
- Adjusted EBITDA1 surged to
$117.8 million , a significant107% increase compared to the prior year period.
- Compared to the prior year period, Direct Operating Cost per Submission2 improved
27% , to an industry leading$501.
- The integration and transformation of e-TeleQuote Insurance, Inc. (“e-TeleQuote”) has driven growth and efficiency gains, delivering significant performance improvements in the 2024 Annual Enrollment Period.
Full-Year 2024 Highlights
- Full-year net revenues reached
$798.9 million , reflecting9% growth compared to the prior year.
- Submissions were 1,016,182, a
23% increase compared to the prior year.
- Net loss of
$7.3 million , an improvement of$144.0 million compared to the prior year.
- Adjusted EBITDA1 of
$120.3 million , a60% increase compared to the prior year.
- Successfully refinanced our credit facility with new five-year term and lender group.
- Supported nearly 3 million Medicare consumers in assessing benefit options in 2024.
- Implemented the PlanFit Save initiative and began receiving health plan compensation for membership retention.
- Remained top partner to health plans based on Submission volume.
“GoHealth’s strong 2024 performance highlights our market-leading, technology-driven approach in the digital Medicare marketplace. While we predicted favorable market dynamics, we were even more pleased by the velocity of our efficiency improvements and the immediate impact of our technology initiatives on profitability. We are energized by the opportunities ahead and are already executing on them," said Vijay Kotte, CEO of GoHealth. "The successful onboarding and optimization of e-TeleQuote, expansion of our health plan partnerships, and continued investment in artificial intelligence and advanced analytics have further strengthened GoHealth’s position as a leading digital Medicare marketplace. As we move into 2025, we continue to focus on driving sustainable, profitable growth, enhancing the consumer experience, and reinforcing our market leadership through continued innovation and operational excellence."
“Our 2024 financial results demonstrate GoHealth’s capacity to achieve exceptional performance through disciplined execution and strategic investment,” said Brendan Shanahan, CFO of GoHealth. “The substantial year-over-year growth in net income and the
| (1) | Adjusted EBITDA is a non-GAAP measure. For a definition of Adjusted EBITDA and a reconciliation to the most comparable GAAP measure, please see below. |
| (2) | Direct Operating Cost per Submission is an operating metric. For a definition of Direct Operating Cost per Submission and an explanation of its calculation, please see below. |
Conference Call Details
The Company will host a conference call today, Thursday, February 27, 2025 at 8:00 a.m. (ET) to discuss its financial results. A live audio webcast of the conference call will be available via GoHealth's Investor Relations website, https://investors.gohealth.com/. A replay of the call will be available via webcast for on-demand listening shortly after the completion of the call.
About GoHealth, Inc.
GoHealth is a leading health insurance marketplace and Medicare-focused digital health company whose purpose is to compassionately ensure consumers’ peace of mind when making healthcare decisions so they can focus on living life. For many of these consumers, enrolling in a health insurance plan is confusing and difficult, and seemingly small differences between health plans may lead to significant out-of-pocket costs or lack of access to critical providers and medicines. GoHealth’s proprietary technology platform leverages modern machine-learning algorithms, powered by over two decades of insurance purchasing behavior, to reimagine the process of matching a health plan to a consumer’s specific needs. Its unbiased, technology-driven marketplace coupled with highly skilled licensed agents has facilitated the enrollment of millions of consumers in Medicare plans since GoHealth’s inception. For more information, visit https://www.gohealth.com.
| Investor Relations: |
| John Shave |
| JShave@gohealth.com |
| Media Relations: |
| Pressinquiries@gohealth.com |
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, (the “Securities Act”) and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). These forward-looking statements are made in reliance upon the safe harbor provision of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical facts contained in this press release may be forward-looking statements. Statements regarding our future results of operations and financial position, business strategy and plans and objectives of management for future operations, including, among others, statements regarding our expected growth, future capital expenditures, debt service obligations, adoption and use of artificial intelligence technologies, the impact on our business from the acquisition of e-TeleQuote and our ability to successfully integrate e-TeleQuote’s operations, technologies and employees into our business, are forward-looking statements.
In some cases, you can identify forward-looking statements by terms such as “may,” “will,” “should,” “aims,” “expects,” “plans,” “anticipates,” “could,” “intends,” “targets,” “projects,” “contemplates,” “believes,” “estimates,” “predicts,” “potential,” “likely,” “future” or “continue” or the negative of these terms or other similar expressions. The forward-looking statements in this press release are only predictions, projections and other statements about future events that are based on current expectations and assumptions. Accordingly, we caution you that any such forward-looking statements are not guarantees of future performance and are subject to risks, assumptions and uncertainties that are difficult to predict. Although we believe that the expectations reflected in these forward-looking statements are reasonable as of the date made, actual results may prove to be materially different from the results expressed or implied by the forward-looking statements.
These forward-looking statements speak only as of the date of this press release and are subject to a number of important factors that could cause actual results to differ materially from those in the forward-looking statements, including the factors described in the sections titled “Summary Risk Factors,” “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in our Annual Report on Form 10-K for the fiscal year ended December 31, 2023 (“2023 Annual Report on Form 10-K”) and our forthcoming Annual Report on Form 10-K for the fiscal year ended December 31, 2024 (“2024 Annual Report on Form 10-K”), as well as our other filings with the Securities and Exchange Commission. The factors described in our 2023 Annual Report on Form 10-K and our forthcoming 2024 Annual Report on Form 10-K should not be construed as exhaustive and should be read together with the other cautionary statements included in this press release, as well as the cautionary statements and other risk factors set forth in the Quarterly Report on Form 10-Q for the first fiscal quarter ended March 31, 2024, the Quarterly Report on Form 10-Q for the second fiscal quarter ended June 30, 2024, the Quarterly Report on Form 10-Q for the third quarter ended September 30, 2024 and in our other filings with the Securities and Exchange Commission.
You should read this press release and the documents that we reference in this press release completely and with the understanding that our actual future results may be materially different from what we expect. We qualify all of our forward-looking statements by these cautionary statements. Except as required by applicable law, we do not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.
Non-GAAP Financial Measures
Throughout this press release, we use a number of non-GAAP financial measures. Non-GAAP financial measures are supplemental measures of our performance that are derived from our consolidated financial information, but which are not presented in our Consolidated Financial Statements prepared in accordance with U.S. generally accepted accounting principles (“GAAP”). We define these non-GAAP financial measures as follows:
- “Adjusted EBITDA” represents, as applicable for the period, EBITDA as further adjusted for certain items summarized in the table furnished below in this press release.
- “Adjusted EBITDA Margin” refers to Adjusted EBITDA divided by net revenues.
- “EBITDA” represents net income (loss) before interest expense, income tax expense (benefit) and depreciation and amortization expense.
We believe that excluding certain items from our GAAP results allows management to better understand our consolidated financial performance from period to period and better project our future consolidated financial performance as forecasts are developed at a level of detail different from that used to prepare GAAP-based financial measures. Moreover, we believe these non-GAAP financial measures provide our stakeholders with useful information to help them evaluate our operating results by facilitating an enhanced understanding of our operating performance and enabling them to make more meaningful period to period comparisons. Adjusted EBITDA is the primary financial performance measure used by management to evaluate the business and monitor the results of operations, as well as a basis for certain compensation programs sponsored by the Company. There are limitations to the use of the non-GAAP financial measures presented in this press release. For example, our non-GAAP financial measures may not be comparable to similarly titled measures of other companies. Other companies, including companies in our industry, may calculate non-GAAP financial measures differently than we do, limiting the usefulness of those measures for comparative purposes.
The non-GAAP financial measures are not meant to be considered as indicators of performance in isolation from or as a substitute for the most directly comparable financial measures prepared in accordance with GAAP and should be read only in conjunction with financial information presented on a GAAP basis. Reconciliations of each of EBITDA, Adjusted EBITDA and Adjusted EBITDA Margin to its most directly comparable GAAP financial measure are presented in the tables furnished below in this press release. We encourage you to review the reconciliations in conjunction with the presentation of the non-GAAP financial measures for each of the periods presented. In future periods, we may exclude similar items, may incur income and expenses similar to these excluded items and may include other expenses, costs and non-routine items.
Key Business Performance and Operating Metrics
In addition to traditional financial metrics, we rely upon certain business and operating metrics to evaluate our business performance and facilitate our operations. The most relevant business and operating metrics are as follows:
- “Direct Operating Cost of Submission” is an operating metric that represents costs directly attributable to Submissions generated during a particular period and excludes costs that are indirect or fixed. Direct Operating Cost of Submission is comprised of the portion of the respective operating expenses for revenue share, marketing and advertising and consumer care and enrollment that are directly related to the Submissions generated in the particular period. Direct Operating Cost of Submission, previously referred to as “Direct Cost of Submission,” reflects a name change only.
- “Direct Operating Cost per Submission” is an operating metric that represents the average performance of Submissions generated during a particular period. Direct Operating Cost per Submission refers to (x) Direct Operating Cost of Submission for a particular period divided by (y) the number of Submissions generated for such period. Direct Operating Cost per Submission, previously referred to as “Direct Cost per Submission” reflects a name change only.
- “Sales/Direct Operating Cost of Submission” represents (x) the numerator of Sales per Submission, as defined below, divided by (y) Direct Operating Cost of Submission. Sales/Direct Operating Cost of Submission, previously referred to as “Sales/Direct Cost of Submission” reflects a name change only.
- “Sales per Submission” is an operating metric that represents the average performance of Submissions generated during a particular period. Sales per Submission measures revenues only from the Submissions generated in the period and excludes items that are unrelated to such Submissions, including any impact of revenue adjustments recorded in the period, but relating to performance obligations satisfied in prior periods. Sales per Submission equals (x) the sum of (i) agency revenues, comprised of the expected amount of initial commission revenue and any renewal commissions to be paid from the health plan partners on such placement as long as the policyholder remains with the same insurance product, as well as partner marketing and other revenue and (ii) non-agency revenues, comprised of the enrollment and engagement services for which cash is collected in advance or in close proximity to the point in time revenue is recognized, divided by (y) the number of Submissions generated for such period.
- “Submission” refers to either (i) a completed application with our licensed agent that is submitted to the health plan partner and subsequently approved by the health plan partner during the indicated period, excluding applications through our Non-Encompass BPO Services or (ii) a transfer by our agent to the health plan partner through the Encompass operating model during the indicated period.
Direct Operating Cost of Submission, Direct Operating Cost per Submission, Sales/Direct Operating Cost of Submission, Sales per Submission and Submissions are key operating metrics we use to understand our underlying financial performance and trends.
Certain Definitions and Key Terms
As used in this press release, unless the context otherwise requires:
- “LTV” refers to the Lifetime Value of Commissions, which we define as aggregate commissions estimated to be collected over the estimated life of all commissionable Submissions for the relevant period based on multiple factors, including but not limited to, contracted commission rates, health plan partner mix and expected policy persistency with applied constraints.
- “Non-Encompass BPO Services” refer to programs in which GoHealth-employed agents are dedicated to certain health plans and agencies we partner with outside of the Encompass operating model.
The following tables set forth the components of our results of operations for the periods indicated (unaudited):
| Three months ended Dec. 31, | |||||||||||||||||||||
| (in thousands, except percentages and per share amounts) | 2024 | 2023 | |||||||||||||||||||
| Dollars | % of Net Revenues | Dollars | % of Net Revenues | $ Change | % Change | ||||||||||||||||
| Net revenues | $ | 389,132 | 100.0 | % | $ | 276,697 | 100.0 | % | $ | 112,435 | 40.6 | % | |||||||||
| Operating expenses: | |||||||||||||||||||||
| Revenue share | 52,236 | 13.4 | % | 41,085 | 14.8 | % | 11,151 | 27.1 | % | ||||||||||||
| Marketing and advertising expense | 99,647 | 25.6 | % | 80,614 | 29.1 | % | 19,033 | 23.6 | % | ||||||||||||
| Consumer care and enrollment | 89,683 | 23.0 | % | 75,199 | 27.2 | % | 14,484 | 19.3 | % | ||||||||||||
| Technology expense | 12,125 | 3.1 | % | 11,596 | 4.2 | % | 529 | 4.6 | % | ||||||||||||
| General and administrative | 31,659 | 8.1 | % | 19,629 | 7.1 | % | 12,030 | 61.3 | % | ||||||||||||
| Amortization of intangible assets | 23,515 | 6.0 | % | 23,514 | 8.5 | % | 1 | — | % | ||||||||||||
| Intangible asset impairment charges | — | — | % | 10,000 | 3.6 | % | (10,000 | ) | (100.0)% | ||||||||||||
| Total operating expenses | 308,865 | 79.4 | % | 261,637 | 94.6 | % | 47,228 | 18.1 | % | ||||||||||||
| Income (loss) from operations | 80,267 | 20.6 | % | 15,060 | 5.4 | % | 65,207 | 433.0 | % | ||||||||||||
| Interest expense | 17,735 | 4.6 | % | 17,751 | 6.4 | % | (16 | ) | (0.1)% | ||||||||||||
| Gain on bargain purchase | (7,129 | ) | (1.8)% | — | — | % | (7,129 | ) | NM | ||||||||||||
| Loss on extinguishment of debt | 10,463 | 2.7 | % | — | — | % | 10,463 | NM | |||||||||||||
| Other (income) expense, net | (1,166 | ) | (0.3)% | (776 | ) | (0.3)% | (390 | ) | 50.3 | % | |||||||||||
| Income (loss) before income taxes | 60,364 | 15.5 | % | (1,915 | ) | (0.7)% | 62,279 | (3252.2)% | |||||||||||||
| Income tax expense (benefit) | 2,389 | 0.6 | % | 379 | 0.1 | % | 2,010 | 530.3 | % | ||||||||||||
| Net income (loss) | 57,975 | 14.9 | % | (2,294 | ) | (0.8)% | 60,269 | (2627.2)% | |||||||||||||
| Net income (loss) attributable to noncontrolling interests | 32,466 | 8.3 | % | (1,068 | ) | (0.4)% | 33,534 | (3139.9)% | |||||||||||||
| Net income (loss) attributable to GoHealth, Inc. | $ | 25,509 | 6.6 | % | $ | (1,226 | ) | (0.4)% | $ | 26,735 | (2180.7)% | ||||||||||
| Net income (loss) per share: | |||||||||||||||||||||
| Net income (loss) per share of Class A common stock — basic | $ | 2.42 | $ | (0.22 | ) | ||||||||||||||||
| Net income (loss) per share of Class A common stock — diluted | $ | 1.56 | $ | (0.22 | ) | ||||||||||||||||
| Weighted-average shares of Class A common stock outstanding — basic | 10,152 | 9,582 | |||||||||||||||||||
| Weighted-average shares of Class A common stock outstanding —diluted | 16,370 | 9,582 | |||||||||||||||||||
| Non-GAAP financial measures: | |||||||||||||||||||||
| EBITDA | $ | 105,026 | $ | 42,684 | |||||||||||||||||
| Adjusted EBITDA | $ | 117,839 | $ | 57,000 | |||||||||||||||||
| Net income (loss) margin | 14.9 | % | (0.8)% | ||||||||||||||||||
| Adjusted EBITDA margin | 30.3 | % | 20.6 | % | |||||||||||||||||
NM = Not meaningful
| Twelve months ended Dec. 31, | |||||||||||||||||||||
| (in thousands, except percentages and per share amounts) | 2024 | 2023 | |||||||||||||||||||
| Dollars | % of Net Revenues | Dollars | % of Net Revenues | $ Change | % Change | ||||||||||||||||
| Net revenues | $ | 798,894 | 100.0 | % | $ | 734,671 | 100.0 | % | $ | 64,223 | 8.7 | % | |||||||||
| Operating expenses: | |||||||||||||||||||||
| Revenue share | 130,612 | 16.3 | % | 158,961 | 21.6 | % | (28,349 | ) | (17.8)% | ||||||||||||
| Marketing and advertising expense | 235,696 | 29.5 | % | 205,042 | 27.9 | % | 30,654 | 15.0 | % | ||||||||||||
| Consumer care and enrollment | 222,414 | 27.8 | % | 209,234 | 28.5 | % | 13,180 | 6.3 | % | ||||||||||||
| Technology expense | 41,046 | 5.1 | % | 43,302 | 5.9 | % | (2,256 | ) | (5.2)% | ||||||||||||
| General and administrative | 82,116 | 10.3 | % | 93,069 | 12.7 | % | (10,953 | ) | (11.8)% | ||||||||||||
| Amortization of intangible assets | 94,057 | 11.8 | % | 94,057 | 12.8 | % | — | — | % | ||||||||||||
| Operating lease impairment charges | — | — | % | 2,687 | 0.4 | % | (2,687 | ) | (100.0)% | ||||||||||||
| Intangible asset impairment charges | — | — | % | 10,000 | 1.4 | % | (10,000 | ) | (100.0)% | ||||||||||||
| Total operating expenses | 805,941 | 100.9 | % | 816,352 | 111.1 | % | (10,411 | ) | (1.3)% | ||||||||||||
| Income (loss) from operations | (7,047 | ) | (0.9)% | (81,681 | ) | (11.1)% | 74,634 | (91.4)% | |||||||||||||
| Interest expense | 72,868 | 9.1 | % | 69,472 | 9.5 | % | 3,396 | 4.9 | % | ||||||||||||
| Gain on bargain purchase | (84,492 | ) | (10.6)% | — | — | % | (84,492 | ) | NM | ||||||||||||
| Loss on extinguishment of debt | 10,463 | 1.3 | % | — | — | % | 10,463 | NM | |||||||||||||
| Other (income) expense, net | (834 | ) | (0.1)% | (37 | ) | — | % | (797 | ) | 2154.1 | % | ||||||||||
| Income (loss) before income taxes | (5,052 | ) | (0.6)% | (151,116 | ) | (20.6)% | 146,064 | (96.7)% | |||||||||||||
| Income tax expense (benefit) | 2,267 | 0.3 | % | 154 | — | % | 2,113 | 1372.1 | % | ||||||||||||
| Net income (loss) | (7,319 | ) | (0.9)% | (151,270 | ) | (20.6)% | 143,951 | (95.2)% | |||||||||||||
| Net income (loss) attributable to noncontrolling interests | (4,391 | ) | (0.5)% | (88,013 | ) | (12.0)% | 83,622 | (95.0)% | |||||||||||||
| Net income (loss) attributable to GoHealth, Inc. | $ | (2,928 | ) | (0.4)% | $ | (63,257 | ) | (8.6)% | $ | 60,329 | (95.4)% | ||||||||||
| Net income (loss) per share: | |||||||||||||||||||||
| Net income (loss) per share of Class A common stock — basic and diluted | $ | (0.66 | ) | $ | (7.19 | ) | |||||||||||||||
| Weighted-average shares of Class A common stock outstanding — basic and diluted | 9,980 | 9,292 | |||||||||||||||||||
| Non-GAAP financial measures: | |||||||||||||||||||||
| EBITDA | $ | 173,706 | $ | 24,104 | |||||||||||||||||
| Adjusted EBITDA | $ | 120,319 | $ | 75,091 | |||||||||||||||||
| Net income (loss) margin | (0.9)% | (20.6)% | |||||||||||||||||||
| Adjusted EBITDA margin | 15.1 | % | 10.2 | % | |||||||||||||||||
NM = Not meaningful
The following table sets forth the reconciliations of GAAP net income (loss) to EBITDA and Adjusted EBITDA for the periods indicated (unaudited):
| Three months ended Dec. 31, | Twelve months ended Dec. 31, | |||||||||||||||
| (in thousands) | 2024 | 2023 | 2024 | 2023 | ||||||||||||
| Net revenues | $ | 389,132 | $ | 276,697 | $ | 798,894 | $ | 734,671 | ||||||||
| Net income (loss) | 57,975 | (2,294 | ) | (7,319 | ) | (151,270 | ) | |||||||||
| Interest expense | 17,735 | 17,751 | 72,868 | 69,472 | ||||||||||||
| Income tax expense (benefit) | 2,389 | 379 | 2,267 | 154 | ||||||||||||
| Depreciation and amortization expense | 26,927 | 26,848 | 105,890 | 105,748 | ||||||||||||
| EBITDA | 105,026 | 42,684 | 173,706 | 24,104 | ||||||||||||
| Gain on bargain purchase1 | (7,129 | ) | — | (84,492 | ) | — | ||||||||||
| Loss on extinguishment of debt2 | 10,463 | — | 10,463 | — | ||||||||||||
| Share-based compensation expense3 | 4,747 | 3,405 | 11,281 | 19,564 | ||||||||||||
| Professional services4 | 2,853 | 335 | 3,671 | 1,548 | ||||||||||||
| Legal fees5 | 1,586 | 148 | 2,917 | 14,840 | ||||||||||||
| Other (income) loss related to the adjustment of liabilities under the Tax Receivable Agreement6 | 293 | 428 | 293 | 428 | ||||||||||||
| Severance costs7 | — | — | 2,480 | 1,920 | ||||||||||||
| Intangible asset impairment charges8 | — | 10,000 | — | 10,000 | ||||||||||||
| Operating lease impairment charges9 | — | — | — | 2,687 | ||||||||||||
| Adjusted EBITDA | $ | 117,839 | $ | 57,000 | $ | 120,319 | $ | 75,091 | ||||||||
| Net income (loss) margin | 14.9 | % | (0.8)% | (0.9)% | (20.6)% | |||||||||||
| Adjusted EBITDA margin | 30.3 | % | 20.6 | % | 15.1 | % | 10.2 | % | ||||||||
| (1) | Represents the excess of the acquisition-date fair value of the net assets acquired over the acquisition-date fair value of the consideration transferred related to the acquisition of e-TeleQuote. |
| (2) | Represents the loss on debt extinguishment related to the write-down of deferred debt discount and debt issuance costs in conjunction with the refinancing of the Term Loan Facilities. |
| (3) | Represents non-cash share-based compensation expense relating to equity awards as well as share-based compensation expense relating to liability classified awards that will be settled in cash. |
| (4) | Represents costs primarily associated with non-routine consulting fees and other professional services. |
| (5) | Represents legal fees, settlement accruals and other expenses related to certain acquisitions, litigation, Credit Agreement amendments and other non-routine legal or regulatory matters. |
| (6) | Represents expense related to the measurement of our Tax Receivable Agreement obligation. |
| (7) | Represents severance costs and other fees associated with a reduction in workforce unrelated to restructuring activities. |
| (8) | Represents an indefinite-lived intangible asset impairment charge for the twelve months ended December 31, 2023. |
| (9) | Represents operating lease impairment charges, reducing the carrying value of the associated ROU assets and leasehold improvements to the estimated fair values. |
The table below depicts the disaggregation of revenue and is consistent with how the Company evaluates its financial performance (unaudited):
| Three months ended Dec. 31, | Twelve months ended Dec. 31, | |||||||||||
| (in thousands) | 2024 | 2023 | 2024 | 2023 | ||||||||
| Medicare Revenue | ||||||||||||
| Agency Revenue | ||||||||||||
| Commission Revenue1 | $ | 278,362 | $ | 94,405 | $ | 506,516 | $ | 355,918 | ||||
| Partner Marketing and Other Revenue | 27,234 | 16,093 | 75,160 | 87,712 | ||||||||
| Total Agency Revenue | 305,596 | 110,498 | 581,676 | 443,630 | ||||||||
| Non-Agency Revenue | 81,566 | 165,383 | 212,289 | 271,969 | ||||||||
| Total Medicare Revenue | 387,162 | 275,881 | 793,965 | 715,599 | ||||||||
| Other Revenue | ||||||||||||
| Non-Encompass BPO Services Revenue | — | — | — | 9,322 | ||||||||
| Other Revenue | 1,970 | 816 | 4,929 | 9,750 | ||||||||
| Total Other Revenue | 1,970 | 816 | 4,929 | 19,072 | ||||||||
| Total Net Revenue | $ | 389,132 | $ | 276,697 | $ | 798,894 | $ | 734,671 | ||||
| (1) | Commission revenue excludes commissions generated through Non-Encompass BPO Services as well as from the sale of individual and family plan insurance products. |
The following table sets forth our balance sheets for the periods indicated (unaudited):
| Dec. 31, | ||||||||
| (in thousands, except per share amounts) | 2024 | 2023 | ||||||
| Assets | ||||||||
| Current assets: | ||||||||
| Cash and cash equivalents | $ | 40,921 | $ | 90,809 | ||||
| Accounts receivable, net of allowance for doubtful accounts of | 4,452 | 250 | ||||||
| Commissions receivable - current | 320,399 | 336,215 | ||||||
| Prepaid expense and other current assets | 34,639 | 49,166 | ||||||
| Total current assets | 400,411 | 476,440 | ||||||
| Commissions receivable - non-current | 733,161 | 575,482 | ||||||
| Operating lease ROU asset | 19,317 | 21,995 | ||||||
| Property, equipment, and capitalized software, net | 29,320 | 26,843 | ||||||
| Intangible assets, net | 302,497 | 396,554 | ||||||
| Other long-term assets | 3,717 | 2,256 | ||||||
| Total assets | $ | 1,488,423 | $ | 1,499,570 | ||||
| Liabilities, Redeemable Convertible Preferred Stock and Stockholders’ Equity | ||||||||
| Current liabilities: | ||||||||
| Accounts payable | $ | 14,591 | $ | 17,705 | ||||
| Accrued liabilities | 121,346 | 86,254 | ||||||
| Commissions payable - current | 98,771 | 127,265 | ||||||
| Short-term operating lease liability | 5,705 | 5,797 | ||||||
| Deferred revenue | 53,720 | 52,403 | ||||||
| Current portion of long-term debt | 39,500 | 75,000 | ||||||
| Other current liabilities | 4,419 | 5,589 | ||||||
| Total current liabilities | 338,052 | 370,013 | ||||||
| Non-current liabilities: | ||||||||
| Commissions payable - non-current | 177,656 | 203,255 | ||||||
| Long-term operating lease liability | 34,900 | 39,547 | ||||||
| Long-term debt, net of current portion | 447,865 | 422,705 | ||||||
| Deferred tax liability | 22,350 | — | ||||||
| Other non-current liabilities | 9,200 | 9,095 | ||||||
| Total non-current liabilities | 691,971 | 674,602 | ||||||
| Commitments and Contingencies | ||||||||
| Series A redeemable convertible preferred stock — | 52,962 | 49,302 | ||||||
| Stockholders’ equity: | ||||||||
| Class A common stock – | 1 | 1 | ||||||
| Class B common stock – | 1 | 1 | ||||||
| Preferred stock – | — | — | ||||||
| Series A-1 convertible preferred stock— | — | — | ||||||
| Treasury stock – at cost; 322 and 173 shares of Class A common stock as of December 31, 2024 and December 31, 2023, respectively. | (4,150 | ) | (2,640 | ) | ||||
| Additional paid-in capital | 669,346 | 654,059 | ||||||
| Accumulated other comprehensive income (loss) | (151 | ) | (127 | ) | ||||
| Accumulated deficit | (423,208 | ) | (420,280 | ) | ||||
| Total stockholders’ equity attributable to GoHealth, Inc. | 241,839 | 231,014 | ||||||
| Non-controlling interests | 163,599 | 174,639 | ||||||
| Total stockholders’ equity | 405,438 | 405,653 | ||||||
| Total liabilities, redeemable convertible preferred stock and stockholders’ equity | $ | 1,488,423 | $ | 1,499,570 | ||||
The following table sets forth the net cash provided by (used in) operating activities for the periods presented (unaudited):
| Net cash provided by (used in) operating activities | Twelve months ended Dec. 31, | ||||||
| 2024 | 2023 | ||||||
| $ | (21,607 | ) | $ | 109,141 | |||
In addition to traditional financial metrics, we rely upon certain business and operating metrics to evaluate our business performance and facilitate our operations. Below are the most relevant business and operating metrics for our single operating and reportable segment.
The following table presents the number of Submissions for the periods presented:
| Submissions | Three months ended Dec. 31, | ||||||||
| 2024 | 2023 | Change | % Change | ||||||
| 481,445 | 288,127 | 193,318 | 67.1 | % | |||||
| Twelve months ended Dec. 31, | |||||||||
| 2024 | 2023 | Change | % Change | ||||||
| 1,016,182 | 826,159 | 190,023 | 23.0 | % | |||||
The following table presents the Sales per Submission for the periods presented:
| Three months ended Dec. 31, | |||||||||||||
| 2024 | 2023 | $ Change | % Change | ||||||||||
| $ | 804 | $ | 957 | $ | (153 | ) | (16.0 | )% | |||||
| Sales Per Submission | |||||||||||||
| Twelve months ended Dec. 31, | |||||||||||||
| 2024 | 2023 | $ Change | % Change | ||||||||||
| $ | 781 | $ | 866 | $ | (85 | ) | (9.8 | )% | |||||
The following table presents the Direct Operating Cost per Submission for the periods presented:
| Three months ended Dec. 31, | |||||||||||||
| 2024 | 2023 | $ Change | % Change | ||||||||||
| $ | 501 | $ | 688 | $ | (187 | ) | (27.2 | )% | |||||
| Direct Operating Cost Per Submission | |||||||||||||
| Twelve months ended Dec. 31, | |||||||||||||
| 2024 | 2023 | $ Change | % Change | ||||||||||
| $ | 578 | $ | 683 | $ | (105 | ) | (15.4 | )% | |||||
The following are our Direct Operating Cost of Submission (in thousands) and Sales/Direct Operating Cost of Submission for the periods presented:
| Three months ended Dec. 31, | Twelve months ended Dec. 31, | |||||||||||
| 2024 | 2023 | 2024 | 2023 | |||||||||
| Direct Operating Cost of Submission | $ | 241,259 | $ | 197,940 | $ | 587,371 | $ | 563,552 | ||||
| Sales/Direct Operating Cost of Submission | 1.6 | 1.4 | 1.4 | 1.3 | ||||||||
FAQ
What was GoHealth's (GOCO) revenue growth in Q4 2024?
How much did GoHealth (GOCO) improve its net income in Q4 2024?
What was GoHealth's (GOCO) submission growth in full-year 2024?
How much did GoHealth (GOCO) reduce its operating costs per submission in Q4 2024?
What was GoHealth's (GOCO) Adjusted EBITDA growth in Q4 2024?
